keyword
MENU ▼
Read by QxMD icon Read
search

SLE therapy

keyword
https://www.readbyqxmd.com/read/28321061/effects-of-denosumab-on-bone-metabolic-markers-and-bone-mineral-density-in-patients-treated-with-glucocorticoids
#1
Masato Sawamura, Atsushi Komatsuda, Masaru Togashi, Hideki Wakui, Naoto Takahashi
Objective We performed a prospective study to determine the efficacy and safety of denosumab on bone metabolic indices and bone mineral density (BMD) in 29 patients receiving long-term glucocorticoids (GCs) who had clinical risk factors for fracture. Methods Among these patients, 16 had systemic lupus erythematosus (SLE), 6 RA, 4 other autoimmune diseases, and 3 renal diseases. All patients received donosumab 60 mg at baseline and 6 months. Serum N-terminal cross-linked telopeptide of type I collagen (NTX) and bone-specific alkaline phosphatase (BAP) levels were measured as bone metabolic indices...
2017: Internal Medicine
https://www.readbyqxmd.com/read/28318807/microrna-302d-targets-irf9-to-regulate-the-ifn-induced-gene-expression-in-sle
#2
Siobhán Smith, Thilini Fernando, Pei Wen Wu, Jane Seo, Joan Ní Gabhann, Olga Piskareva, Eoghan McCarthy, Donough Howard, Paul O'Connell, Richard Conway, Phil Gallagher, Eamonn Molloy, Raymond L Stallings, Grainne Kearns, Lindsy Forbess, Mariko Ishimori, Swamy Venuturupalli, Daniel Wallace, Michael Weisman, Caroline A Jefferies
Systemic lupus erythematosus (SLE) is a complex disease targeting multiple organs as a result of overactivation of the type I interferon (IFN) system, a feature currently being targeted by multiple biologic therapies against IFN-α. We have identified an estrogen-regulated microRNA, miR-302d, whose expression is decreased in SLE patient monocytes and identify its target as interferon regulatory factor (IRF)-9, a critical component of the transcriptional complex that regulates expression of interferon-stimulated genes (ISGs)...
March 17, 2017: Journal of Autoimmunity
https://www.readbyqxmd.com/read/28317620/lupus-hepatitis-and-autoimmune-hepatitis-lupoid-hepatitis
#3
REVIEW
Avinash Adiga, Kenneth Nugent
Liver dysfunction occurs in approximately 50% of patients with systemic lupus erythematosus (SLE), and patients with SLE and elevated liver enzymes can present a complicated and difficult differential diagnosis. Lupus hepatitis and autoimmune hepatitis are 2 immunologic conditions involving the liver, which can have similar clinical, laboratory and systemic presentations, leading to difficulties in diagnosis. Physicians need to be aware of these 2 hepatic diseases as diagnosis and appropriate therapy need to occur early in the disease course to prevent progression to advanced liver disease...
April 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28301792/systemic-lupus-erythematosus-an-update
#4
Vera Golder, Alberta Hoi
Systemic lupus erythematosus (SLE) is a chronic multisystem autoimmune disease predominantly affecting women of childbearing age. New classification criteria for SLE have greater sensitivity and therefore improve the diagnostic certainty for some patients, especially those who may previously have been labelled as having undifferentiated symptoms. Uncontrolled disease activity leads to irreversible end-organ damage, which in turn increases the risk of premature death; early and sustained control of disease activity can usually be achieved by conventional immunosuppressant therapy...
March 20, 2017: Medical Journal of Australia
https://www.readbyqxmd.com/read/28300427/annexin-a1-as-a-target-for-managing-murine-pristane-induced-systemic-lupus-erythematosus
#5
Nikolina Mihaylova, Silviya Bradyanova, Petroslav Chipinski, Melinda Herbáth, Stela Chausheva, Dobroslav Kyurkchiev, József Prechl, Andrey I Tchorbanov
Systemic lupus erythematosus (SLE) is a polygenic pathological disorder which involves multiple organs. Self-specific B cells play a main role in the lupus pathogenesis by generating autoantibodies as well as by serving as important autoantigen-presenting cells. Autoreactive T lymphocytes, on the other hand, are responsible for B cell activation and proliferation, and cytokine production. Therefore, both factors promote the idea that a down-modulation of activated self-reactive T and B cells involved in the pathogenic immune response is a reasonable approach for SLE therapy...
March 16, 2017: Autoimmunity
https://www.readbyqxmd.com/read/28296238/chinese-sle-treatment-and-research-group-cstar-registry-viii-influence-of-socioeconomic-and-geographical-variables-on-disease-phenotype-and-activity-in-chinese-patients-with-sle
#6
Yongjing Cheng, Mengtao Li, Jiuliang Zhao, Zhizhong Ye, Caifeng Li, Xiaofeng Li, Ping Zhu, Zhengang Wang, Yi Zheng, Xiangpei Li, Miaojia Zhang, Cibo Huang, Xiaofeng Zeng
AIM: The aim of this study was to estimate the influence of socioeconomic and geographical variables on disease phenotype and activity of systemic lupus erythematosus (SLE) in a Chinese population. METHODS: Data on 904 therapy-naïve SLE patients from the Chinese SLE Treatment and Research Group (CSTAR), which is a nation-wide database of SLE patients, were used to evaluate the influence of socioeconomic status (SES) and geographical regions on disease phenotypes...
March 13, 2017: International Journal of Rheumatic Diseases
https://www.readbyqxmd.com/read/28294088/an-update-on-diet-and-nutritional-factors-in-systemic-lupus-erythematosus-management
#7
Marina Aparicio-Soto, Marina Sánchez-Hidalgo, Catalina Alarcón-de-la-Lastra
Systemic lupus erythematosus (SLE) is a chronic inflammatory and autoimmune disease characterised by multiple organ involvement and a large number of complications. SLE management remains complicated owing to the biological heterogeneity between patients and the lack of safe and specific targeted therapies. There is evidence that dietary factors can contribute to the geoepidemiology of autoimmune diseases such as SLE. Thus, diet therapy could be a promising approach in SLE owing to both its potential prophylactic effects, without the side effects of classical pharmacology, and its contribution to reducing co-morbidities and improving quality of life in patients with SLE...
March 15, 2017: Nutrition Research Reviews
https://www.readbyqxmd.com/read/28285807/a-brighter-side-to-thalidomide-its-potential-use-in-immunological-disorders
#8
REVIEW
David Millrine, Tadamitsu Kishimoto
Thalidomide and its derivatives are immunomodulatory drugs (IMiDs) known for their sedative, teratogenic, anti-angiogenic, and anti-inflammatory properties. Commonly used in the treatment of cancers such as multiple myeloma and myelodysplastic syndrome (MDS), IMiDs have also been used in the treatment of an inflammatory skin pathology associated with Hansen's disease/leprosy. They have also shown promise in the treatment of autoimmune disorders including systemic lupus erythmatosus (SLE) and inflammatory bowel disease (IBD)...
March 9, 2017: Trends in Molecular Medicine
https://www.readbyqxmd.com/read/28285445/differential-impact-of-systemic-lupus-erythematosus-and-rheumatoid-arthritis-on-health-related-quality-of-life
#9
Benjamin Chaigne, Axel Finckh, Deshire Alpizar-Rodriguez, Delphine Courvoisier, Camillo Ribi, Carlo Chizzolini
PURPOSE: This study examined and compared health-related quality of life (QoL) in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). METHODS: We included patients from two multicentric cohorts, the Swiss SLE cohort study (SSCS) and the Swiss Clinical Quality Management Program for RA (SCQM-RA). Patients were matched by age, sex and disease duration using the propensity score. Disease activity was assessed by SELENA-SLEDAI in SLE and by DAS-28 in RA...
March 11, 2017: Quality of Life Research
https://www.readbyqxmd.com/read/28284231/support-for-phosphoinositol-3-kinase-and-mtor-inhibitors-as-treatment-for-lupus-using-in-silico-drug-repurposing-analysis
#10
Daniel Toro-Domínguez, Pedro Carmona-Sáez, Marta E Alarcón-Riquelme
BACKGROUND: Systemic lupus erythematosus (SLE) is an autoimmune disease with few treatment options. Current therapies are not fully effective and show highly variable responses. In this regard, large efforts have focused on developing more effective therapeutic strategies. Drug repurposing based on the comparison of gene expression signatures is an effective technique for the identification of new therapeutic approaches. Here we present a drug-repurposing exploratory analysis using gene expression signatures from SLE patients to discover potential new drug candidates and target genes...
March 11, 2017: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/28280970/belimumab-use-clinical-outcomes-and-glucocorticoid-reduction-in-patients-with-systemic-lupus-erythematosus-receiving-belimumab-in-clinical-practice-settings-results-from-the-observe-canada-study
#11
Zahi Touma, Amyn Sayani, Christian A Pineau, Isabelle Fortin, Mark Matsos, George A Ecker, Andrew Chow, Sandra Iczkovitz
To describe the characteristics of patients receiving belimumab, overall patterns of systemic lupus erythematosus (SLE) care, clinical outcomes, and changes in glucocorticoid dose following 6 months of therapy with belimumab, and healthcare resource utilization in belimumab users in Canadian clinical practice settings. Retrospective multicenter medical chart review study of adult patients with SLE who were prescribed belimumab as part of usual care and who received ≥8 infusions or 6 months of treatment...
March 9, 2017: Rheumatology International
https://www.readbyqxmd.com/read/28279836/autologous-hematopoietic-stem-cell-transplantation-in-systemic-lupus-erythematosus-and-antiphospholipid-syndrome-a-systematic-review
#12
REVIEW
Alessia Leone, Massimo Radin, Ahlam M Almarzooqi, Jamal Al-Saleh, Dario Roccatello, Savino Sciascia, Munther Khamashta
BACKGROUND: Hematopoietic stem cell transplantation (HSCT) has been proposed as a therapeutic option for patients with Systemic Lupus Erythematosus (SLE) refractory to standard therapy. This therapeutic approach has been applied to other severe autoimmune diseases refractory to standard therapy with promising results. AIM: To systematically review the literature and analyze the available evidence on HSCT therapy in patients with SLE and antiphospholipid syndrome (APS), with a focus on therapy efficacy and occurrence of adverse events...
March 7, 2017: Autoimmunity Reviews
https://www.readbyqxmd.com/read/28265845/novel-treatments-in-lupus
#13
REVIEW
Vasileios C Kyttaris
PURPOSE OF REVIEW: The treatment of systemic lupus erythematosus (SLE) still depends on non-specific immunosuppression. Herein, we review promising targeted therapies that have the potential to change this therapeutic paradigm. RECENT FINDINGS: Besides the FDA-approved B lymphocyte stimulator (BLyS) inhibitor, belimumab, interferon-α represents a promising treatment target, albeit with modest effectiveness primarily in non-renal SLE. Preclinical and early-phase clinical trials using biologics and small molecules targeting B and T cell activation as well as the cross-talk between these cells also show promise...
March 2017: Current Rheumatology Reports
https://www.readbyqxmd.com/read/28265683/-recurrent-thromboembolisms-despite-full-anticoagulation-in-a-patient-with-antiphospholipid-syndrome
#14
S Wernicke, K Selleng, S B Felix, A Greinacher, F Hammer
We report on a female patient with confirmed secondary antiphospholipid syndrome (APS) due to underlying systemic lupus erythematosus (SLE). Despite a thromboplastin time within the normal range (international normalized ratio, INR) under treatment with a vitamin K antagonist (VKA), a recurrent thrombotic event occurred, this time as pulmonary embolism due to bilateral deep vein thrombosis. Despite an INR value in the therapeutic range, clotting factors II, VII, IX and X were found to be insufficiently decreased suggesting inefficient anticoagulation...
March 6, 2017: Der Internist
https://www.readbyqxmd.com/read/28262212/type-b-insulin-resistance-in-peru
#15
Henry Zelada, Dante Gamarra, Hugo Arbañil, Helard Manrique
Type B insulin resistance (IR) is a rare autoimmune disease characterized by the presence of insulin receptor autoantibodies, resulting in a marked IR inducing hyperglycemia. Our first case is a 42-year-old female with a history of RA, SLE and Hashimoto-thyroiditis that presented with cachexia, acanthosis-nigricans, hirsutism, negative anti-insulin-ab and glucose level between 400 to 700 mg/dl, despite a total insulin dose of 1000 IU/day. She received pulses of cyclophosphamide along with prednisone. One year later the patient was off insulin and with HbA1c of 5...
March 2017: American Journal of the Medical Sciences
https://www.readbyqxmd.com/read/28258497/treatment-of-pediatric-onset-lupus-nephritis-a-proposal-of-optimal-therapy
#16
REVIEW
Hiroshi Tanaka, Kensuke Joh, Tadaatsu Imaizumi
Lupus nephritis (LN) is one of the major clinical manifestations of systemic lupus erythematosus (SLE) which occurs frequently in the early stages of pediatric-onset cases. Since SLE is a chronic disease associated with frequent disease flares and effective and safe maintenance therapy is required for achieving a favorable outcome, optimal treatment for LN in pubertal patients is a great challenge that remains to be overcome. Although its etiology remains unclear, it has been reported that the innate and adaptive immune systems have been reported to play an important role in the pathogenesis of SLE...
March 3, 2017: Clinical and Experimental Nephrology
https://www.readbyqxmd.com/read/28250139/healthcare-and-research-priorities-of-adolescents-and-young-adults-with-systemic-lupus-erythematosus-a-mixed-methods-study
#17
David J Tunnicliffe, Davinder Singh-Grewal, Jonathan C Craig, Martin Howell, Peter Tugwell, Fiona Mackie, Ming-Wei Lin, Sean G O'Neill, Angelique F Ralph, Allison Tong
OBJECTIVE: Managing juvenile-onset systemic lupus erythematosus (SLE) is particularly challenging. The disease may be severe, adolescent patients have complex medical and psychosocial needs, and patients must navigate the transition to adult services. To inform patient-centered care, we aimed to identify the healthcare and research priorities of young patients with SLE and describe the reasons underpinning their priorities. METHODS: Face-to-face, semistructured interviews and focus groups were conducted with patients with SLE, aged from 14 to 26 years, from 5 centers in Australia...
March 1, 2017: Journal of Rheumatology
https://www.readbyqxmd.com/read/28245854/development-of-the-systemic-lupus-erythematosus-steroid-questionnaire-ssq-a-novel-patient-reported-outcome-tool-to-assess-the-impact-of-oral-steroid-treatment
#18
Susan D Mathias, Pamela Berry, Jane De Vries, Anca Askanase, Katie Pascoe, Hilary H Colwell, David J Chang
BACKGROUND: Oral glucocorticoids (steroids) are the mainstay of treatment for systemic lupus erythematosus (SLE), but their use is often associated with short- and long-term side effects. Following a literature review and discussions with patients with SLE, clinicians, and payers, a need was identified for a comprehensive SLE-specific tool that can be used to evaluate the side effects and benefits of steroids over time from a patient perspective. The objective of this study was to develop a patient-reported outcome (PRO) measure to assess general impact (baseline burden), benefits, side effects, and impacts associated with the use of oral steroids in patients with SLE...
February 28, 2017: Health and Quality of Life Outcomes
https://www.readbyqxmd.com/read/28243944/serum-levels-of-p-glycoprotein-and-persistence-of-disease-activity-despite-treatment-in-patients-with-systemic-lupus-erythematosus
#19
Edsaul Emilio Perez-Guerrero, Jorge Ivan Gamez-Nava, Jose Francisco Muñoz-Valle, Ernesto German Cardona-Muñoz, David Bonilla-Lara, Nicte Selene Fajardo-Robledo, Arnulfo Hernan Nava-Zavala, Teresa Arcelia Garcia-Cobian, Ana Rosa Rincón-Sánchez, Jessica Daniela Murillo-Vazquez, David Cardona-Müller, Maria Luisa Vazquez-Villegas, Sylvia Elena Totsuka-Sutto, Laura Gonzalez-Lopez
Around 25% of patients with systemic lupus erythematosus (SLE) could be refractory to conventional therapies. P-glycoprotein expression on cell surface has been implied on drug resistance, however, to date, it is unknown if P-gp serum levels are associated with SLE disease activity. Evaluate the association of serum P-gp levels and SLE with disease activity despite treatment. A cross-sectional study was conducted on 93 female SLE patients, all receiving glucocorticoids at stable doses for the previous 6 months before to baseline...
February 27, 2017: Clinical and Experimental Medicine
https://www.readbyqxmd.com/read/28243455/the-use-of-rituximab-in-newly-diagnosed-patients-with-systemic-lupus-erythematosus-long-term-steroid-saving-capacity-and-clinical-effectiveness
#20
Borja Gracia-Tello, Amara Ezeonyeji, David Isenberg
BACKGROUND: Previous reports indicate that treating patients with lupus (SLE) at or close to the time of diagnosis successfully without using any, or minimal, corticosteroids by using B-cell depletion (BCD) is possible in the short-term. It is not however known whether using BCD is as effective or reduces corticosteroid use in the long-term. We report the long-term (up to 7 years) use of BCD with respect to its steroid-saving capacity and clinical effectiveness in newly diagnosed SLE...
2017: Lupus Science & Medicine
keyword
keyword
57199
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"